PDF herunterladen
CC BY-NC-ND 4.0 · Endosc Int Open 2021; 09(07): E979-E985
DOI: 10.1055/a-1460-7776
Original article

Underutilization of prophylactic rectal indomethacin and pancreatic duct stent for prevention of post-ERCP Pancreatitis

Abdulfatah Issak
1   Division of Gastroenterology and Hepatology, Metrohealth Medical Center, Case Western Reserve University, Cleveland, Ohio, United States
2   Department of Internal Medicine, Metrohealth Medical Center, Case Western Reserve University, Cleveland, Ohio, United States
,
Abbinaya Elangovan
1   Division of Gastroenterology and Hepatology, Metrohealth Medical Center, Case Western Reserve University, Cleveland, Ohio, United States
2   Department of Internal Medicine, Metrohealth Medical Center, Case Western Reserve University, Cleveland, Ohio, United States
,
Roy D. Ferguson
1   Division of Gastroenterology and Hepatology, Metrohealth Medical Center, Case Western Reserve University, Cleveland, Ohio, United States
2   Department of Internal Medicine, Metrohealth Medical Center, Case Western Reserve University, Cleveland, Ohio, United States
,
Nisheet Waghray
1   Division of Gastroenterology and Hepatology, Metrohealth Medical Center, Case Western Reserve University, Cleveland, Ohio, United States
2   Department of Internal Medicine, Metrohealth Medical Center, Case Western Reserve University, Cleveland, Ohio, United States
,
Dalbir S. Sandhu
3   Division of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, United States
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

Background and study aims Incidence of Post-ERCP pancreatitis (PEP) ranges from 1 % to 10 % in unselected patients and as high as 25 % to 30 % in high-risk patients. Rectal indomethacin administered before or immediately after an ERCP and prophylactic pancreatic duct stent placement (PPS) are associated with a reduction in the incidence of PEP. We sought to investigate the utilization rate for prophylactic rectal indomethacin and PPS in average and high-risk patients undergoing ERCP between 2014 and 2019.

Patients and methods We performed a retrospective analysis in the IBM Explorys database, a pooled, national de-identified clinical database of over 72 million unique patients from 26 health care networks and 300 hospitals across the United States from 2014 to 2019. Average and high-risk patients undergoing ERCP were identified using Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) diagnosis codes. PEP was defined by the presence of SNOMED CT diagnosis of acute pancreatitis and an inpatient admission within 5 days of an ERCP procedure.

Results Out of 31,050 adults who had undergone ERCP from 2014 to 2019, only 10,500 individuals (33.8 %) had a PEP prophylaxis. Rectal indomethacin and PPS accounted for 82.4 % and 12.9 % respectively. Individuals with three risk factors had the highest PEP rates followed by individuals with two risk factors.

Conclusions Only one-third of all patients undergoing ERCP received prophylaxis in the form of rectal indothemacin and/or PPS in this large population-based data. Increased implementation of prophylactic use is needed in patients undergoing ERCP as supported by current guidelines.



Publikationsverlauf

Eingereicht: 24. September 2020

Angenommen: 23. Februar 2021

Artikel online veröffentlicht:
17. Juni 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Einführung zu:

Underutilization of societal guidelines: occasional or widespread?Endosc Int Open 2021; 09(07): E986-E988
DOI: 10.1055/a-1399-8891

 

  • References

  • 1 Cotton PB. Are low-volume ERCPists a problem in the United States? A plea to examine and improve ERCP practice-NOW. Gastrointest Endosc 2011; 74: 161-166
    CrossrefPubMedSuche in Google Scholar
  • 2 Peery AF, Crockett SD, Murphy CC. et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the united states: update 2018. [published correction appears in Gastroenterology 2019; 156: 1936] Gastroenterology 2019; 156: 254-272.e11
    CrossrefPubMedSuche in Google Scholar
  • 3 Andriulli A, Loperfido S, Napolitano G. et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102: 1781-1788
    CrossrefPubMedSuche in Google Scholar
  • 4 Yaghoobi M, Alzahrani MA, McNabb-Baltar J. et al. Rectal indomethacin prevents moderate to severe post-ERCP pancreatitis and death and should be used before the procedure: a meta-analysis of aggregate subgroup data. J Can Assoc Gastroenterol 2018; 1: 67-75
    CrossrefPubMedSuche in Google Scholar
  • 5 Avila P, Holmes I, Kouanda A. et al. Practice patterns of post-ERCP pancreatitis prophylaxis techniques in the United States: a survey of advanced endoscopists. Gastrointest Endosc 2020; 91: 568-573.e2
    CrossrefPubMedSuche in Google Scholar
  • 6 Testoni PA, Mariani A, Giussani A. et al. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study. Am J Gastroenterol 2010; 105: 1753-1761
    CrossrefPubMedSuche in Google Scholar
  • 7 Dumonceau JM, Andriulli A, Elmunzer BJ. et al. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – updated June 2014. Endoscopy 2014; 46: 799-815
    Thieme ConnectPubMedSuche in Google Scholar
  • 8 ASGE Standards of Practice Committee. Chandrasekhara V, Khashab MA. et al. Adverse events associated with ERCP. Gastrointest Endosc 2017; 85: 32-47
    CrossrefPubMedSuche in Google Scholar
  • 9 Testoni PA. Preventing post-ERCP pancreatitis: where are we?. JOP 2003; 4: 22-32
    PubMedSuche in Google Scholar
  • 10 Kochar B, Akshintala VS, Afghani E. et al. Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials. Gastrointest Endosc 2015; 81: 143-149.e9
    CrossrefPubMedSuche in Google Scholar
  • 11 Fazel A, Quadri A, Catalano MF. et al. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. . Gastrointest Endosc 2003; 57: 291-294
    CrossrefPubMedSuche in Google Scholar
  • 12 Singh P, Das A, Isenberg G. et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 2004; 60: 544-550
    CrossrefPubMedSuche in Google Scholar
  • 13 Tarnasky PR. Mechanical prevention of post-ERCP pancreatitis by pancreatic stents: results, techniques, and indications. JOP 2003; 4: 58-67
    PubMedSuche in Google Scholar
  • 14 Phillip V, Pukitis A, Epstein A. et al. Pancreatic stenting to prevent post-ERCP pancreatitis: a randomized multicenter trial. Endosc Int Open 2019; 7: E860-E868
    Thieme ConnectPubMedSuche in Google Scholar
  • 15 Elmunzer BJ, Waljee AK, Elta GH. et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008; 57: 1262-1267
    CrossrefPubMedSuche in Google Scholar
  • 16 He X, Zheng W, Ding Y. et al. Rectal indomethacin is protective against pancreatitis after endoscopic retrograde cholangiopancreatography: systematic review and meta-analysis. Gastroenterol Res Pract 2018; 2018: 9784841
    PubMedSuche in Google Scholar
  • 17 Elmunzer BJ, Scheiman JM, Lehman GA. et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-1422
    CrossrefPubMedSuche in Google Scholar
  • 18 Yokoe M, Takada T, Mayumi T. et al. Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015. J Hepatobiliary Pancreat Sci 2015; 22: 405-432
    CrossrefPubMedSuche in Google Scholar
  • 19 Hanna MS, Portal AJ, Dhanda AD. et al. UK wide survey on the prevention of post-ERCP pancreatitis. Frontline Gastroenterol 2014; 5: 103-110
    CrossrefPubMedSuche in Google Scholar
  • 20 IBM. The IBM Explorys Platform. https://www.ibm.com/downloads/cas/4P0QB9JN
    PubMed
  • 21 Kaelber DC, Foster W, Gilder J. et al. Patient characteristics associated with venous thromboembolic events: a cohort study using pooled electronic health record data. JAMIA 2012; 19: 965-972
    PubMedSuche in Google Scholar
  • 22 Nadkarni PM, Darer JA. Migrating existing clinical content from ICD-9 to SNOMED. JAMIA 2010; 17: 602-607
    PubMedSuche in Google Scholar
  • 23 Smith ZL, Elmunzer BJ, Cooper GS. et al. Real-world practice patterns in the era of rectal indomethacin for prophylaxis against post-ERCP pancreatitis in a high-risk cohort. Am J Gastroenterol 2020; 115: 934-940
    CrossrefPubMedSuche in Google Scholar
  • 24 Barkin JA, Souto EO, Barkin JS. et al. Rectal Indomethacin should be used routinely in all patients for the prevention of post-ERCP pancreatitis. Gastrointest Endosc 2017; 895: 687-688
    CrossrefPubMedSuche in Google Scholar
  • 25 Inamdar S, Han D, Passi M. et al. Rectal indomethacin is protective against post-ERCP pancreatitis in high-risk patients but not average-risk patients: a systematic review and meta-analysis. Gastrointest Endosc 2017; 85: 67-75
    CrossrefPubMedSuche in Google Scholar
  • 26 Del Olmo Martínez L, Velayos Jiménez B, Almaraz Gómez A. Rectal diclofenac does not prevent post-ERCP pancreatitis in consecutive high-risk and low-risk patients. Rev Esp Enferm Dig 2018; 110: 505-509
    CrossrefPubMedSuche in Google Scholar
  • 27 Katoh T, Kawashima K, Fukuba N. et al. Low-dose rectal diclofenac does not prevent post-ERCP pancreatitis in low- or high-risk patients. J Gastroenterol Hepatol 2020; 35: 1247-1253
    CrossrefPubMedSuche in Google Scholar
  • 28 Andriulli A, Leandro G, Federici T. et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65: 624-632
    CrossrefPubMedSuche in Google Scholar
  • 29 Bhatia V, Ahuja V, Acharya SK. et al. A randomized controlled trial of valdecoxib and glyceryl trinitrate for the prevention of post-ERCP pancreatitis. J Clin Gastroenterol 2011; 45: 170-176
    CrossrefPubMedSuche in Google Scholar
  • 30 Shao LM, Chen QY, Chen MY. et al. Nitroglycerin in the prevention of post-ERCP pancreatitis: a meta-analysis. Dig Dis Sci 2010; 55: 1-7
    CrossrefPubMedSuche in Google Scholar
  • 31 Sherman S, Blaut U, Watkins JL. et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc 2003; 58: 23-29
    CrossrefPubMedSuche in Google Scholar
  • 32 Akbar A, Abu Dayyeh BK, Baron TH. et al. Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 778-783
    CrossrefPubMedSuche in Google Scholar
  • 33 Freeman ML, DiSario JA, Nelson DB. et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-434
    CrossrefPubMedSuche in Google Scholar
  • 34 Sherman S, Lehman GA. ERCP- and endoscopic sphincterotomy-induced pancreatitis. Pancreas 1991; 6: 350-367
    CrossrefPubMedSuche in Google Scholar
  • 35 Tarnasky PR, Palesch YY, Cunningham JT. et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998; 115: 1518-1524
    CrossrefPubMedSuche in Google Scholar
  • 36 Loperfido S, Angelini G, Benedetti G. et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48: 1-10
    CrossrefPubMedSuche in Google Scholar